Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) announced the grant of 50,000 restricted stock units (RSUs) to Mark Johnson, its newly appointed Senior Vice President of Product Development, effective May 6, 2022. The RSUs will fully vest on the one-year anniversary of his hire, contingent on his continued service with the company. The compensation, approved by the Compensation Committee, serves as an inducement for his acceptance of the position. Jaguar, a commercial-stage pharmaceuticals company, focuses on developing plant-based medications for gastrointestinal distress in humans and animals.

Positive

• Appointment of Mark Johnson as Senior VP of Product Development could bring fresh perspectives to the company.
• Granting RSUs as an inducement demonstrates the company's commitment to attracting talent.

Negative

• None.

SAN FRANCISCO, CA / ACCESSWIRE / May 6, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective May 6, 2022, the Company granted 50,000 restricted stock units (RSUs) to Mark Johnson, a new employee hired to serve as Senior Vice President, Product Development at the Company.

All of these RSUs vest in full on the one-year anniversary of this new employee's date of hire. These RSUs were granted as an inducement material to this new employee's acceptance of employment with the Company and were approved by the Compensation Committee of the Board. Vesting of the RSUs is subject to this employee's continued service with Jaguar through the applicable vesting date.

About Jaguar Health, Jaguar Animal Health, Napo Pharmaceuticals, & Napo Therapeutics

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Animal Health is a tradename of Jaguar Health. Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe.

For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View source version on accesswire.com:
https://www.accesswire.com/700120/Jaguar-Health-Announces-New-Employee-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635c4

FAQ

What new position was announced for Mark Johnson at Jaguar Health?

Mark Johnson was appointed as Senior Vice President of Product Development.

What is the significance of the RSUs granted to Mark Johnson?

The 50,000 restricted stock units (RSUs) serve as an inducement for his acceptance of employment, vesting fully after one year.

When did Jaguar Health grant RSUs to Mark Johnson?

Jaguar Health granted the RSUs effective May 6, 2022.

How many RSUs were granted to Mark Johnson?

Jaguar Health granted 50,000 RSUs to Mark Johnson.

What is Jaguar Health's focus as a company?

Jaguar Health focuses on developing plant-based, non-opioid medications for gastrointestinal distress.